Penny Pasley

​​​​​​Penny is a senior associate in Bell Gully's industry-leading competition team. Penny advises on a broad range of competition matters including mergers and joint ventures, collaborative activities, cartel investigations and misuse of market power.​

Penny returned to Bell Gully following several years at leading London firm Linklaters where she was a managing associate. She brings with her a wealth of experience and understanding of international competition law from both advising high profile clients in the European Union and completing a Postgraduate Diploma in EU Competition Law at King's College in London.

Recent New Zealand work highlights include advising ASB Bank on the Commerce Commission’s most recent market study and Ampol Limited on obtaining Commerce Commission clearance for its $1.7 billion acquisition of Z Energy.

Penny is ranked as a 'Leading associate' for competition law in The Legal 500 Asia Pacific 2024.

ASB Bank
Advising ASB Bank on the Commerce Commission’s market study into personal banking services.

Ampol’s acquisition of Z Energy
Advising Ampol Limited on obtaining Commerce Commission clearance for its $1.7 billion acquisition of Z Energy, supported by a divestment undertaking in relation to the sale of Ampol’s Gull business.

Cartel and market conduct investigations
Acting on various Commerce Commission investigations into alleged cartel and other market behaviour conduct, including advising large international companies in relation to a Commerce Commission investigation into potential resale price maintenance, and an investigation into alleged cartel conduct and an associated successful application for leniency.

Acquisition of the MBCC Group by Sika AG
Advising Sika AG on the regulatory requirements of its acquisition of MBCC Group. This matter was cleared by the Commerce Commission subject to a complex global divestment.

​Mylan N.V. merger with Upjohn​
Advised Mylan N.V. on obtaining competition clearance for their merger with Upjohn Inc (a wholly owned subsidiary of Pfizer Inc), a transaction which included a payment of $12bn to Pfizer as partial consideration for Upjohn.